Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers which are identified as having an aberrant activation of the Notch pathway. Such activation has long been implicated in multiple solid tumor and blood-related cancers and has often been associated with more aggressive cancers. Ayala Pharmaceuticals is initially focused on ultra-orphan indications such as salivary gland cancer with an additional focus on larger patient population indications, including triple negative breast cancer as well as an aggressive form of Leukemia.
- Alpha TAU Medical Ltd.
- Ayala Pharmaceuticals Inc.
- Brainsway Ltd.
- Chemomab Therapeutics Ltd.
- Elbit Vision Systems Ltd.
- Foamix Pharmaceuticals Ltd.
- Galooli Ltd.
- Gamida Cell Ltd.
- Intec Pharma Ltd.
- Kahr Medical Ltd.
- Kamada Ltd.
- Lightricks Ltd.
- Mapi Pharma Ltd.
- MeMed Diagnostics Ltd.
- Polus Tech Pty Ltd.
- PolyPid Ltd.
- ReWalk Robotics Ltd.
- SuperDerivatives Inc.
- Syqe Medical Ltd.
- Tipa Corp. Ltd.
- Trax Ltd.
- Veev
- Yotpo Ltd.
- Other